The shares of the leading chemical manufacturers gained up to 2 percent after Quant Mutual Fund bought 10.51 lakh equity shares in the company in an NSE bulk deal.
With a market capitalization of Rs 5,490.12 crore, the shares of Aarti Pharmalabs Ltd were trading at Rs 604.40 per share, decreasing around 0.84 percent as compared to the previous closing price of Rs 609.50 apiece.
As of March 2024, Baron Emerging Markets Fund, a foreign portfolio investor, holds 9.14 lakh equity shares which is equivalent to 1.01 percent of the company, out of which FII sold 8.61 lakh equity shares at an average price of Rs 573 per share, valued at Rs 49.38 crore. However, Quant Mutual Fund has bought 10.51 lakh equity shares which is equivalent to 1.16 percent in Aarti Pharmalabs at an average price of Rs 575.83 per share.
Looking into Aarti Pharmalabs Ltd’s performance, revenue increased by 4.3 percent from Rs 485 Crore in Q4FY23 to Rs 506 Crore in Q4FY24. During the same time frame, net profit increased by 51 percent from Rs 43 crore to Rs 65 crore.
Aarti Pharmalabs is the largest Indian manufacturer of Xanthine Derivatives, including Caffeine, Theophylline Anhydrous, Aminophylline, Etophylline, and Theophylline that find applications in beverages, nutraceuticals, and pharmaceutical industries
The company operates two dedicated plants with a combined capacity of about 5,000 MTPA for producing Xanthine Derivatives. With a global market share of 15-20%, APL holds a significant presence in the global Xanthine derivatives industry.
Aarti Pharmalabs is a top small molecule Contract Development and Manufacturing Organization (CDMO/CMO) in India. Provides services for drug substance projects such as NCEs, APIs, RSMs, and intermediates to worldwide creative pharmaceutical and biotech firms. Currently working with 16 innovators and major pharmaceutical corporations.
Aarti Pharmalabs Limited provides contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacture for pharmaceutical and biotech companies, focusing on the Ph-I/II/III, launch, and commercial stages.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
